Desitin to develop and sell Zogenix' sumatriptan DosePro in EU

24 March 2008

Zogenix, a privately-held US specialty drugmaker, has entered into a license agreement to grant exclusive rights in the European Union to Germany's Desitin Pharmaceuticals GmbH to develop and commercialize Zogenix' late-stage, single-use, needle-free product for migraine headache, sumatriptan DosePro. The investigational agent, which incorporates Zogenix' DosePro needle-free drug-delivery technology, has demonstrated bioequivalence to UK drug major GlaxoSmithKline's Imitrex STATdose System (sumatriptan injection) in a US pivotal trial. Under the terms of the deal, Desitin will oversee and be responsible for expenses related to all clinical development, regulatory approvals and commercialization efforts required to market and sell sumatriptan DosePro across Europe. Zogenix will be responsible for the manufacture and supply of commercial product, and will receive a transfer price payment on manufactured product and royalties.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight